Suchergebnisse

El objetivo de este trabajo es visibilizar, y ello como herramienta de cambio, la interpretación y la aplicación de la normativa vigente en materia de Violencia de Género en el estado Español y en concreto en lo que a la declaración de la víctima se refiere.Para ello, se realizará un análisis de un procedimiento real de Violencia de Género cuya competencia correspondió a la Audiencia Provincial de Madrid, que servirá para ejemplificar la exposición de los distintos puntos del presente artículo. Así mismo, acudiremos a la jurisprudencia del Tribunal Supremo y del Tribunal Constitucional que determinan los criterios orientativos a seguir a la hora de valorar la declaración de la víctima-testigo en caso de que sea la única prueba de cargo. Ello nos llevará a reflexionar, por un lado, sobre la subjetividad de las pautas doctrinales recogidas por los altos tribunales para determinar la veracidad y credibilidad de la declaración de la víctima-testigo de Violencia de Género; y por otro lado, sobre los fuertes prejuicios y estereotipos de género que pueden llevar a la/el Juez a considerar no creíble el testimonio de mujeres víctimas de Violencia de Género.La particularidad de este tipo de delitos, que suelen cometerse en la intimidad y sin testigos, es la dificultad probatoria que los caracteriza: nos enfrentan a una realidad en materia procesal penal en la que prevalece la valoración del juez de primera instancia respecto de la prueba practicada, no revisable ni repetible en segunda instancia, y ello al amparo de los principios de inmediación y contradicción, que forman parte del derecho a un proceso con todas las garantías.

PMCID: PMC3539432; NIHMSID: NIHMS430346.-- et al. ; A first research development progress report of the Chromosome 19 Consortium with members from Sweden, Norway, Spain, United States, China and India, a part of the Chromosome-centric Human Proteome Project (C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted using a subset with 125 isotope-labeled peptides. We applied an annotation strategy with triple quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data within and in between these instrumental set-ups. LC-MS conditions were outlined by multiplex assay developments, followed by MRM assay developments. SRM was applied to biobank samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer patients. The antibody production has been initiated for more than 1200 genes from the entire chromosome 19, and the progress developments are presented. We developed a dedicated transcript microarray to serve as the mRNA identifier by screening cancer cell lines. NAPPA protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first development delivery. We have introduced an IT-infrastructure utilizing a LIMS system that serves as the key interface for the research teams to share and explore data generated within the project. The cross-site data repository will form the basis for sample processing, including biological samples as well as patient samples from national Biobanks. © 2012 American Chemical Society. ; This work was supported by grants from the Swedish Academy of Pharmaceutical Sciences who is the core founder our consortium, Swedish Research Council, the Swedish Foundation for Strategic Research, Vinnova, Ingabritt & Arne Lundbergs forskningsstiftelse, the Crafoord Foundation and by Thermo Fisher Scientific for mass spectrometry instrument support. T.E.F. is supported by the Mobilitas Program sponsored by the European Union Social Fund and administered by the Estonian Science Foundation. We gratefully acknowledge financial support to M.F. from Health Institute Carlos III of Spain (ISCIII, FIS PI02114) and M.G.-G. is supported by a PhD scholarship of ISCIII FI08/00721. C.L.N. is supported by the Cancer Prevention and Research Institute of Texas and the University of Texas Medical Branch. [11-0624]; National Cancer Institute [R33 CA 127768-03, R01CA160816, and P50-CA92629]; Sidney Kimmel Center for Prostate and Urologic Cancers; and David H. Koch through the Prostate Cancer Foundation. ; Peer Reviewed

© 2020 by the authors. ; Natural products are the ideal basis for the design of novel efficient molecular entities. Podophyllotoxin, a naturally occurring cyclolignan, is an example of natural product which displays a high versatility from a biological activity point of view. Based on its unique chemical structure, different derivatives have been synthesized presenting the original antitumoral properties associated with the compound, i.e., the tubulin polymerization inhibition and arising anti-topoisomerase II activity from structural modifications on the cyclolignan skeleton. In this report, we present a novel conjugate or hybrid which chemically combines both biological activities in one single molecule. Chemical design has been planned based in our lead compound, podophyllic aldehyde, as an inhibitor of tubulin polymerization, and in etoposide, an approved antitumoral drug targeting topoisomerase II. The cytotoxicity and selectivity of the novel synthetized hybrid has been evaluated in several cell lines of different solid tumors. In addition, these dual functional effects of the novel compound have been also evaluated by molecular docking approaches. ; Financial support came from Spanish MINECO (CTQ2015-68175-R, AGL2016-79813-C2-2-R), Junta de Castilla y León (BIO/SA07/15), ISCIII-RICET Network (RD16/0027/0018) cofinanced by the Fondo Social Europeo of the European Union (Fondos FEDER–EU) and USAL (Financiación GIR). Fundación Solórzano (FS/23-2015) has also sponsored this work. The Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by Grant No. PT13/0001, of the PE I+D+I 2013–2016, funded by ISCIII and FEDER.

© 2020 by the authors. ; Natural products are the ideal basis for the design of novel efficient molecular entities. Podophyllotoxin, a naturally occurring cyclolignan, is an example of natural product which displays a high versatility from a biological activity point of view. Based on its unique chemical structure, different derivatives have been synthesized presenting the original antitumoral properties associated with the compound, i.e., the tubulin polymerization inhibition and arising anti-topoisomerase II activity from structural modifications on the cyclolignan skeleton. In this report, we present a novel conjugate or hybrid which chemically combines both biological activities in one single molecule. Chemical design has been planned based in our lead compound, podophyllic aldehyde, as an inhibitor of tubulin polymerization, and in etoposide, an approved antitumoral drug targeting topoisomerase II. The cytotoxicity and selectivity of the novel synthetized hybrid has been evaluated in several cell lines of different solid tumors. In addition, these dual functional effects of the novel compound have been also evaluated by molecular docking approaches. ; Financial support came from Spanish MINECO (CTQ2015-68175-R, AGL2016-79813-C2-2-R), Junta de Castilla y León (BIO/SA07/15), ISCIII-RICET Network (RD16/0027/0018) cofinanced by the Fondo Social Europeo of the European Union (Fondos FEDER–EU) and USAL (Financiación GIR). Fundación Solórzano (FS/23-2015) has also sponsored this work. The Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by Grant No. PT13/0001, of the PE I+D+I 2013–2016, funded by ISCIII and FEDER.

"This is the peer reviewed version of the following article: Oroval, Mar, Paula Díez, Elena Aznar, Carmen Coll, María Dolores Marcos, Félix Sancenón, Reynaldo Villalonga, and Ramón Martínez-Máñez. 2016. Self-Regulated Glucose-Sensitive Neoglycoenzyme-Capped Mesoporous Silica Nanoparticles for Insulin Delivery. Chemistry - A European Journal 23 (6). Wiley: 1353 60. doi:10.1002/chem.201604104, which has been published in final form at https://doi.org/10.1002/chem.201604104. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving." ; [EN] We describe herein the preparation of glucose-sensitive capped mesoporous silica nanoparticles for insulin delivery. The new material consists of an expanded-pore nanometric silica support grafted with 1-propyl-1-H-benzimidazole groups, loaded with fluorescein isothiocyanate-labeled insulin (FITC-Ins) and capped by the formation of inclusion complexes between cyclodextrin-modified glucose oxidase (CD-GOx) and the benzimidazole groups grafted on the mesoporous support. Insulin delivery from the gated material in simulated blood plasma was assessed upon addition of glucose. Glucose is transformed by GOx into gluconic acid, which promoted the dethreading of the benzimidazole-CD-GOx inclusion complexes, allowing cargo release. Small quantities of this support would be needed to release the amount of insulin necessary to decrease diabetic blood glucose concentrations to regular levels. ; The authors thank the Spanish Government (projects CTQ2011-24355, MAT2015-64139-C4-1-R, CTQ2014-58989-P, and AGL2015-70235-C2-2-R (MINECO/FEDER)) and the Generalitat Valenciana (project PROMETEOII/2014/047) for support. M.O. thanks the Universitat Politecnica de Valencia for her FPI grant. P.D. thanks the Ministerio de Economia y Competitividad for her FPI grant (BES-2012-054066). C.C. thanks the Generalitat Valenciana for her postdoctoral contract VALi+D. ; Oroval, M.; Díez, P.; Aznar, E.; Coll Merino, MC.; Marcos Martínez, MD.; Sancenón ...

[EN] A new gated nanodevice design able to control cargo delivery using glucose as a trigger and cyclodextrin-modified glucose oxidase as a capping agent is reported. ; Financial support from the Spanish Government (projects MAT2012-38429-C04-01 and CTQ2011-24355), Generalitat Valenciana (project PROMETEO/2009/016), UPV (project SP20120795) and Ramon y Cajal Programme (to R. V.) is gratefully acknowledged. ; Aznar Gimeno, E.; Villalonga, R.; Giménez Morales, C.; Sancenón Galarza, F.; Marcos Martínez, MD.; Martínez Mañez, R.; Díez, P. (2013). Glucose-triggered release using enzyme-gated mesoporous silica nanoparticles. Chemical Communications. 49(57):6391-6393. https://doi.org/10.1039/c3cc42210k ; S ; 6391 ; 6393 ; 49 ; 57 ; Coll, C., Bernardos, A., Martínez-Máñez, R., & Sancenón, F. (2012). Gated Silica Mesoporous Supports for Controlled Release and Signaling Applications. Accounts of Chemical Research, 46(2), 339-349. doi:10.1021/ar3001469 ; Aznar, E., Martínez-Máñez, R., & Sancenón, F. (2009). Controlled release using mesoporous materials containing gate-like scaffoldings. Expert Opinion on Drug Delivery, 6(6), 643-655. doi:10.1517/17425240902895980 ; Cotí, K. K., Belowich, M. E., Liong, M., Ambrogio, M. W., Lau, Y. A., Khatib, H. A., … Stoddart, J. F. (2009). Mechanised nanoparticles for drug delivery. Nanoscale, 1(1), 16. doi:10.1039/b9nr00162j ; Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992). Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature, 359(6397), 710-712. doi:10.1038/359710a0 ; Lai, C.-Y., Trewyn, B. G., Jeftinija, D. M., Jeftinija, K., Xu, S., Jeftinija, S., & Lin, V. S.-Y. (2003). A Mesoporous Silica Nanosphere-Based Carrier System with Chemically Removable CdS Nanoparticle Caps for Stimuli-Responsive Controlled Release of Neurotransmitters and Drug Molecules. Journal of the American Chemical Society, 125(15), 4451-4459. doi:10.1021/ja028650l ; Park, C., Oh, K., Lee, S. C., & Kim, C. (2007). ...

"This is the peer reviewed version of the following article: Llopis-Lorente, Antoni, Paula Díez, Cristina de la Torre, Alfredo Sánchez, Félix Sancenón, Elena Aznar, María D. Marcos, Paloma Martínez-Ruíz, Ramón Martínez-Máñez, and Reynaldo Villalonga. 2017. Enzyme-Controlled Nanodevice for Acetylcholine-Triggered Cargo Delivery Based on Janus Au-Mesoporous Silica Nanoparticles. Chemistry - A European Journal 23 (18). Wiley: 4276 81. doi:10.1002/chem.201700603, which has been published in final form at https://doi.org/10.1002/chem.201700603. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving." ; [EN] This work reports a new gated nanodevice for acetylcholine-triggered cargo delivery. We prepared and characterized Janus Au-mesoporous silica nanoparticles functionalized with acetylcholinesterase on the Au face and with supramolecular b-cyclodextrin: benzimidazole inclusion complexes as caps on the mesoporous silica face. The nanodevice is able to selectively deliver the cargo in the presence of acetylcholine via enzyme-mediated acetylcholine hydrolysis, locally lowering the pH and opening the supramolecular gate. Given the key role played by ACh and its relation with Parkinson's disease and other nervous system diseases, we believe that these findings could help design new therapeutic strategies. ; A.L.L. is grateful to "La Caixa" Banking Foundation for his PhD fellowship. The authors are gratitude to the Spanish Government (MINECO Projects MAT2012-38429-C04-01, MAT2015-64139-C4-1, CTQ2014-58989-P and CTQ2015-71936-REDT) and the Generalitat Valencia (Project PROMETEOII/2014/047) for support. The Comunidad de Madrid (S2013/MIT-3029, Programme NANOAVANSENS) is also gratefully acknowledged. ; Llopis-Lorente, A.; Díez, P.; De La Torre-Paredes, C.; Sanchez, A.; Sancenón Galarza, F.; Aznar, E.; Marcos Martínez, MD. (2017). Enzyme-Controlled Nanodevice for Acetylcholine-Triggered Cargo Delivery Based on Janus Au-Mesoporous Silica Nanoparticles. Chemistry - ...